AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/02/22

Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.19 (+51.3% Y/Y) and the consensus Revenue Estimate is $36.4M (+148.3% Y/Y). Over the last 1 year, AUPH has be...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third quarter 2022 on Thursday, November 3, 2022, before markets open. Aurinia’s management team will host a conference call/webcast at ...

Aurinia Stock ( NASDAQ:AUPH ) Aurinia Pharmaceuticals ( NASDAQ:AUPH ), a Canadian biotech company, has fallen back into the red just one day after posting a gain of approximately 13%. This comes at the same time that H.C. Wainwright has taken steps to address...

Just a day after a ~13% rise, Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) is back in the red even as H.C. Wainwright moved to address questions surrounding the departures of the company's Chief Medical Officer and Executive Vice President of Research. The r...

Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) lost ~4% pre-market Friday after the company announced that its Chief Medical Officer, Neil Solomons, and Executive Vice President, Research, Robert Huizinga, will resign from their positions effective Oct. 31. ...

Summary The key catalyst for Travere in the near term is the PDUFA date for sparsentan for the treatment of IgA nephropathy in early November. With a positive outcome anticipated, there might not be enough reward to hold the stock into the event. Given the recent slow launches...

Five abstracts underscore the long-term safety and efficacy of voclosporin, including in Latino patients and patients with Class V lupus nephritis Data presentation on pre-clinical asset AUR200 reinforces Aurinia’s commitment to autoimmune disease Aurinia Phar...

The European Commission has approved Aurinia Pharmaceuticals' ( NASDAQ: AUPH ) Lupkynis (voclosporin) for lupus nephritis. The approval triggers a $30M milestone payment from partner Otsuka Pharmaceutical ( OTCPK:OTSKF )( OTCPK:OTSKY ). A decision on Lupkyn...

Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in July 2022 LUPKYNIS is the first oral medicine approved in both the U.S. and Europe for the treatment of adults living with active lupus nephritis Approval...

Summary Today, we circle back on biopharma name Aurinia Pharmaceuticals for the first time since last September. The company has been the subject of many takeover rumors, is seeing good revenue growth, but has some litigation worries at the moment. An investment analysis follo...